Literature DB >> 32460624

The amount of cytokine-release defines different shades of Sars-Cov2 infection.

S Bindoli1, M Felicetti1, P Sfriso1, A Doria1.   

Abstract

The recent outbreak of coronavirus disease (COVID 19), spreading from China all around the world in early 2020, has led scientists to investigate the immuno-mediated mechanisms underlying the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) infection. Depending on the amount of cytokines released as the result of the immunological activation induced by SARS-CoV2, three major clinical phenotypes can be identified: "mild",symbolized as a "drizzle" of cytokines, severe as a "storm", and critical as a "hurricane". In patients with mild symptoms, the release of pro-inflammatory cytokines is balanced to obtain a defense response against the virus which is often self-limiting and overcomes without tissue damage. In severe phenotype, resembling a "cytokine-release syndrome", SARS-CoV2 causes the lysis of the immune-mediators leading to a cytokine storm able to induce lung epithelium damage and acute respiratory distress syndrome. In critical patients, the immune response may become uncontrolled, thus the cytokine burst resembles a form of secondary hemophagocytic lymphohistiocytosis which may result in a multi organ failure. In addition to the standard of care, an immune-modulatory therapy tailored to each one of the different phenotypes should be used in order to prevent or reduce the release of cytokines responsible for organ damage and disease progression.

Entities:  

Keywords:  COVID-19; CRS; HLH/MAS; SARS-CoV2; cytokines

Mesh:

Substances:

Year:  2020        PMID: 32460624      PMCID: PMC7427176          DOI: 10.1177/1535370220928964

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  59 in total

Review 1.  The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.

Authors:  Changfeng Hu; Lu Lu; Jie-Ping Wan; Chengping Wen
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

2.  Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis.

Authors:  L D Bos; L R Schouten; L A van Vught; M A Wiewel; D S Y Ong; O Cremer; A Artigas; I Martin-Loeches; A J Hoogendijk; T van der Poll; J Horn; N Juffermans; C S Calfee; M J Schultz
Journal:  Thorax       Date:  2017-04-27       Impact factor: 9.139

3.  Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis.

Authors:  Raymond S M Wong; Alan Wu; K F To; Nelson Lee; Christopher W K Lam; C K Wong; Paul K S Chan; Margaret H L Ng; L M Yu; David S Hui; John S Tam; Gregory Cheng; Joseph J Y Sung
Journal:  BMJ       Date:  2003-06-21

Review 4.  In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy.

Authors:  Jorge Garcia Borrega; Philipp Gödel; Maria Adele Rüger; Özgür A Onur; Alexander Shimabukuro-Vornhagen; Matthias Kochanek; Boris Böll
Journal:  Hemasphere       Date:  2019-03-29

5.  Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome.

Authors:  Wei-Kung Wang; Shey-Ying Chen; I-Jung Liu; Chuan-Liang Kao; Hui-Ling Chen; Bor-Liang Chiang; Jann-Tay Wang; Wang-Hwei Sheng; Po-Ren Hsueh; Chao-Fu Yang; Pan-Chyr Yang; Shan-Chwen Chang
Journal:  Clin Infect Dis       Date:  2004-09-01       Impact factor: 9.079

6.  An interferon-gamma-related cytokine storm in SARS patients.

Authors:  Kao-Jean Huang; Ih-Jen Su; Michel Theron; Yi-Chun Wu; Shu-Kuan Lai; Ching-Chuan Liu; Huan-Yao Lei
Journal:  J Med Virol       Date:  2005-02       Impact factor: 2.327

7.  Effective treatment of severe COVID-19 patients with tocilizumab.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

Review 8.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  Semin Immunopathol       Date:  2017-05-02       Impact factor: 9.623

Review 9.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.

Authors:  Hussin A Rothan; Siddappa N Byrareddy
Journal:  J Autoimmun       Date:  2020-02-26       Impact factor: 7.094

Review 10.  Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.

Authors:  Yixuan Wang; Yuyi Wang; Yan Chen; Qingsong Qin
Journal:  J Med Virol       Date:  2020-03-29       Impact factor: 20.693

View more
  16 in total

1.  Prevalence and coagulation correlation of anticardiolipin antibodies in patients with COVID-19.

Authors:  Hui Zeng; Meihong Cai; Han Xue; Wen Xie; Xinghua Long
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

2.  Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients.

Authors:  Nausheen N Hakim; Jeffrey Chi; Coral Olazagasti; Johnson M Liu
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-24

Review 3.  Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review.

Authors:  Sara Bindoli; Alessandro Giollo; Paola Galozzi; Andrea Doria; Paolo Sfriso
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-22

Review 4.  Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?

Authors:  Johnson M Liu; Jeffrey Chi
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-22

5.  Protease-activated receptor 1 as a potential therapeutic target for COVID-19.

Authors:  Emanuel S Rovai; Tomaz Alves; Marinella Holzhausen
Journal:  Exp Biol Med (Maywood)       Date:  2020-12-10

6.  COVID-19 Pathophysiology Predicts That Ischemic Stroke Occurrence Is an Expectation, Not an Exception-A Systematic Review.

Authors:  Tissa Wijeratne; Sheila Gillard Crewther; Carmela Sales; Leila Karimi
Journal:  Front Neurol       Date:  2021-01-28       Impact factor: 4.003

7.  HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients.

Authors:  Álvaro Tamayo-Velasco; Pedro Martínez-Paz; María Jesús Peñarrubia-Ponce; Ignacio de la Fuente; Sonia Pérez-González; Itziar Fernández; Carlos Dueñas; Esther Gómez-Sánchez; Mario Lorenzo-López; Estefanía Gómez-Pesquera; María Heredia-Rodríguez; Irene Carnicero-Frutos; María Fe Muñoz-Moreno; David Bernardo; Francisco Javier Álvarez; Eduardo Tamayo; Hugo Gonzalo-Benito
Journal:  J Clin Med       Date:  2021-05-08       Impact factor: 4.241

8.  Relative expression of proinflammatory molecules in COVID-19 patients who manifested disease severities.

Authors:  Shireen Nigar; Sm Tanjil Shah; Md Ali Ahasan Setu; Sourav Dutta Dip; Habiba Ibnat; M Touhidul Islam; Selina Akter; Iqbal Kabir Jahid; M Anwar Hossain
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

Review 9.  Drug repurposing and cytokine management in response to COVID-19: A review.

Authors:  Luana Heimfarth; Mairim Russo Serafini; Paulo Ricardo Martins-Filho; Jullyana de Souza Siqueira Quintans; Lucindo José Quintans-Júnior
Journal:  Int Immunopharmacol       Date:  2020-08-31       Impact factor: 4.932

Review 10.  Impact of Corona Virus Disease-19 (COVID-19) pandemic on gastrointestinal disorders.

Authors:  Amol Nanak Singh Baryah; Vandana Midha; Ramit Mahajan; Ajit Sood
Journal:  Indian J Gastroenterol       Date:  2020-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.